Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
FibrosisLiver2 moreConduct a community intervention study that will 1) validate a screening approach to identify patients at risk for advanced NAFLD in the obese or T2DM population, and 2) test whether semaglutide treatment is effective for the management of significant fibrosis due to NAFLD in high-risk patients.
HTD1801 in Adults With Nonalcoholic Steatohepatitis and Liver Fibrosis Who Have Type 2 Diabetes...
Nonalcoholic Steatohepatitis (NASH)Type 2 DiabetesA phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
Liver Enzymes and Metabolic Risk Factors Response to Laser Acupuncture Versus Cupping Therapy in...
Fatty Liverfatty liver disease is characterized by low antioxidants, disturbed lipid metabolism, cardioautonomic functions, and elevated blood measures (glucose, inflammatory markers, liver enzymes)
ENDOSCOPIC ULTRASOUND-GUIDED LARGE DIAMETER LUMEN-APPOSING METAL STENT GASTRO-GASTROSTOMY FOR BYPASS...
HypoglycemiaGastric Outlet Obstruction3 moreThe primary objective of this open-label pilot study is to investigate whether an endoscopically placed lumen apposing metal stent is an effective alternative to surgery in patients that have a clear indication for reversal of their gastric bypass.
Effect of Indian Hepatoprotective Diet in Reversibility of NAFLD
Non-Alcoholic Fatty Liver DiseaseMetabolic SyndromeThe modality of lifestyle modification including low calorie diets along with normal protein and moderate physical activity is the safest standard medical treatment for NAFLD in general. There are many benefits of weight loss to the patients with NAFLD. Besides the improvement in the features of metabolic syndrome, weight loss with IHPD would certainly improve the overall vitality and well being of the patients. The results of study will help to delineate a protocolized care for the management of NAFLD with metabolic syndrome thus helping other patients also in the future.
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as...
Non-alcoholic SteatohepatitisNovo Nordisk is developing a combination of 2 medicines (NNC0194-0499 and semaglutide) for the treatment of nonalcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used to treat type 2 diabetes and obesity. The study is being done to see how 2 medicines (NNC0194-0499 and semaglutide) are absorbed, transported, and eliminated from the body in a combination formulation. Participants will either get NNC0194-0499 and semaglutide in a combination formulation or the separate formulations. Which treatment participants get is decided by chance. The study will last for either 13 or 33 weeks. The duration is decided by chance.
Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease
NAFLDObjectives To evaluate the efficacy, safety, and tolerability of lubiprostone in patients with nonalcoholic fatty liver disease (NAFLD). This study will include 100 patients with nonalcoholic fatty liver disease (NAFLD) recruited from the specialized NAFLD outpatient's clinic in National Hepatology and Tropical Medicine Research Institute (NHTMRI). Study design: Randomized controlled trial.
Safety Study of OA-235i in Subjects With Nonalcoholic Steatohepatitis
Nonalcoholic SteatohepatitisNonalcoholic Fatty LiverThis study is a Phase 1, first-in-human single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of OA-235i in subjects with nonalcoholic steatohepatitis.
Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients...
MetforminObesity9 moreThe purpose of this study is to analyze the effects of GLP-1RA on blood glucose, body weight, glucose and lipid metabolism and fat distribution in overweight/obese patients with type 2 diabetes mellitus.
A Research Study Looking Into Blood and Urine Levels of the Medicine NNC0194-0499 in the Body and...
Non-alcoholic Steatohepatitis (NASH)Novo Nordisk is developing the study medicine NNC0194-0499 for the treatment of non-alcoholic steatohepatitis (NASH). NASH is a serious disease where fat, inflammation and scar tissue builds up in the liver. In this study the blood and urine levels of NNC0194-0499 will be compared in people with various degrees of reduced kidney function to the blood and urine levels in people with normal kidney function, after administration of one dose of 30 milligrams (mg) NNC0194-0499. Participant will only get the study medicine in one injection into a skinfold in the thigh (subcutaneous). The study will last for about 66 days including a screening phase of up to 28 days prior to dosing.